Suppr超能文献

[123I-β-甲基-碘苯基-十五烷酸心肌闪烁显像在无明显缺血性心脏病的糖尿病患者中的应用]

[123I-beta-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease].

作者信息

Shinmura K, Tani M, Suganuma Y, Hasegawa H, Kawamura M, Nakamura Y, Hashimoto J, Kubo A

机构信息

Department of Geriatric Medicine, Keio University School of Medicine, Tokyo.

出版信息

J Cardiol. 1995 Jul;26(1):23-32.

PMID:7666341
Abstract

Fatty acid metabolism in the myocardium is affected by metabolic disorders such as diabetes mellitus. We evaluated 123I-beta-methyl-iodophenyl-pentadecanoic acid (BMIPP) myocardial scintigraphy in 15 diabetes mellitus patients without overt coronary heart disease. Patients with overt coronary heart disease were excluded by careful history taking, resting electrocardiography, treadmill exercise testing, echocardiography and resting 201Tl scintigraphy. Patients with remarkably impaired left ventricular (LV) systolic function (%FS < 30%) were also excluded. BMIPP uptake scores as the ratio of heart/mediastinum (H/M) and liver/mediastinum (L/M) at 20 minutes after injection were analyzed and compared with clinical profile, serum parameters, and LV parameters obtained from echocardiography. Five of the 15 patients showed abnormal BMIPP images; two patients showed a decreased uptake in the inferior segments, while three showed a diffuse decrease in BMIPP uptake. Body mass index (BMI), fasting blood sugar (FBS), HbAlc, IRI, and LV end-diastolic diameter (LVEDD) were higher in these five patients with abnormal BMIPP findings (abnormal BMIPP group vs normal BMIPP group, BMI: 29 vs 23 kg/m2, p < 0.05; FBS: 178 vs 114 mg/dl, p < 0.01; HbAlc: 7.6 vs 6.2%, p < 0.01; IRI: 18.5 vs 9.5 microU/ml, p < 0.01; LVEDD: 52 vs 44 mm, p < 0.05). 123I-metaiodobenzyl-guanidine (MIBG) scintigraphy in the five patients with abnormal BMIPP uptake showed more severe defects than in the 10 patients with normal BMIPP imaging. BMIPP scintigraphy demonstrated a significant correlation between H/M and L/M by BMIPP (r = 0.74, p < 0.01). Furthermore, correlation between H/M by BMIPP scintigraphy and clinical parameters (BMI, systolic blood pressure, FBS, HbAlc, IRI) were found, suggesting that diabetes mellitus patients without over coronary heart disease show abnormal BMIPP imaging when their general glucose utility and 123I-MIBG uptake are severely impaired (progression of insulin resistance and sympathetic nerve involvement). BMIPP scintigraphy may be useful in investigating the pathogenesis and subclinical abnormality of diabetic heart.

摘要

心肌中的脂肪酸代谢会受到诸如糖尿病等代谢紊乱的影响。我们对15例无明显冠心病的糖尿病患者进行了123I-β-甲基-碘代苯基-十五烷酸(BMIPP)心肌闪烁显像检查。通过详细询问病史、静息心电图、平板运动试验、超声心动图和静息201Tl闪烁显像排除了明显冠心病患者。左心室(LV)收缩功能显著受损(%FS<30%)的患者也被排除。分析注射后20分钟时作为心脏/纵隔(H/M)和肝脏/纵隔(L/M)比值的BMIPP摄取分数,并与临床资料、血清参数以及超声心动图获得的LV参数进行比较。15例患者中有5例显示BMIPP图像异常;2例患者下壁节段摄取减少,3例患者BMIPP摄取呈弥漫性减少。这5例BMIPP检查结果异常的患者(BMIPP异常组与BMIPP正常组相比)的体重指数(BMI)、空腹血糖(FBS)、糖化血红蛋白(HbAlc)、胰岛素释放指数(IRI)和LV舒张末期内径(LVEDD)更高(BMI:29 vs 23 kg/m2,p<0.05;FBS:178 vs 114 mg/dl,p<0.01;HbAlc:7.6 vs 6.2%,p<0.01;IRI:18.5 vs 9.5 microU/ml,p<0.01;LVEDD:52 vs 44 mm,p<0.05)。5例BMIPP摄取异常患者的123I-间碘苄胍(MIBG)闪烁显像显示的缺损比10例BMIPP显像正常的患者更严重。BMIPP闪烁显像显示BMIPP的H/M与L/M之间存在显著相关性(r=0.74,p<0.01)。此外,发现BMIPP闪烁显像的H/M与临床参数(BMI、收缩压、FBS、HbAlc、IRI)之间存在相关性,这表明无明显冠心病的糖尿病患者当其总体葡萄糖利用和123I-MIBG摄取严重受损时(胰岛素抵抗和交感神经受累进展)会出现BMIPP显像异常。BMIPP闪烁显像可能有助于研究糖尿病性心脏的发病机制和亚临床异常。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验